Newsletter | April 24, 2026

04.24.26 -- Why Open-Source AI Models Matter For Computational Drug Discovery

Welcome to the Drug Discovery Online newsletter, delivering weekly updates on the latest developments in discovery and early-stage drug development. Based on your professional interests, we believe you’ll find it useful for improving research efficiency, staying current on emerging discovery technologies, and identifying the right partners to advance your programs. If not, you can unsubscribe at any time.

FEATURED EDITORIAL

Why Open-Source AI Models Matter For Computational Drug Discovery

By Drug Discovery Online Live

Panel explored open source AI tools in drug discovery, from structure prediction to antibiotics, with leaders from Boltz, OpenFold, McMaster University Drug Discovery Online.

Beyond KRAS G12C: New Approaches For Drugging The Undruggable

By John Taylor, Cancer Research Horizons

RAS was considered among the holy grail of oncology targets, but over the past decade, this has started to change. A second wave is making its way through R&D to address current shortcomings.

A State Of Stress: Developing Therapeutics Rooted In Cell Behavior

A conversation with Yerem Yeghiazarians, Soley Therapeutics

We caught up with Yerem Yeghiazarians, CEO of Soley Therapeutics, to discuss how capturing the complexity of disease requires going beyond a single target.

INDUSTRY INSIGHTS

Automated DNA Size Selection For Flexible NGS Workflow Integration

Application Note | INTEGRA Biosciences

Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.

Reducing Wastewater Incineration And Carbon Emissions

Article | By Dr. Niklaus Künzle and Dr. Andreas Sieber, Lonza

To reduce CO2 emissions and recycle higher volumes of solvent, manufacturers must engineer approaches with flexible technologies that can be adapted to accommodate different products.

Spray Drying For Innovative Dry Powder Inhaler Combination Formulations

Article | Lonza

Combination therapies delivered directly to the lung by dry powder inhalants are an effective means of reducing patient burden. Read about case studies that illustrate the potential for improving care.

Quantifying Lentiviral Physical Titer

Application Note | By Miroslav Vraneš, Anne Schieren, Philipp Rink, et al., QIAGEN

Streamline lentiviral vector analytics with our direct RT-dPCR method. Achieve precise, reproducible results to accelerate safe, effective gene therapies with enhanced quality control.

SPONSOR

PEGS Boston – The Essential Protein & Antibody Engineering Summit

May 11-15, 2026 | Boston, MA + Virtual

The PEGS Boston Summit is where the future of biologics takes shape. For 20+ years, it’s been the go-to event for protein and antibody engineering, drug development, immunotherapy, radiotherapy, and AI/ML-driven biologics. New in 2026: a focus on peptides. With 350+ presentations, hands-on sessions, and a buzzing exhibit hall, PEGS connects you with the leaders defining the future of biologics. 

SOLUTIONS

Services For Advancing mRNA-LNPs From Bench To Clinic

Cytiva

Advancing Flow Cytometry Through Automated Analysis

BD Biosciences

SPONSOR

With 1900+ attendees, TIDES USA, May 11-14, 2026, at Boston's Hynes Convention Center, is North America's leading forum for advancing oligonucleotide, peptide, mRNA, genome editing, and delivery innovations. This event bridges research to reality, fostering collaboration, and breakthrough solutions. Explore cutting-edge workshops, tracks, and exhibits while connecting with global pioneers like Robert Langer and Kiran Musunuru. Register early for any early bird savings and save an additional 10% with VIP code ADVRNA10 at checkout!